

Table S1. Clinicopathological features of reported cases of tibial *EWSR1::NFATC2* sarcoma.

First author, year	Age, years/Sex	Tumor size, cm	Molecular tests	Localization	Original diagnosis	Surgery	Local recurrence, months	Metastasis, months	Chemotherapy	Outcome/Follow-up	(Refs.)
Watson S, 2018	12/F	NR	NR	NR	ES	NR	NR	NR	NR	NR/NR	(13)
Shaheen M, 2022	21/M	8.2	NR	Diaphyseal cortex	NR	NR	NR	NR	NR	NED/8 mo	(14)
Perret R, 2020	27/M	8.0	NR	NR	NR	Yes	No	No	NAC (VDC/IE)	NED/102 mo	(8)
Diaz-Perez JA, 2019	28/M	4.2	NR	NR	NR	Yes	No	No	NAC (ES regimen)	(NED/8.7 mo)	(15)
Perret R, 2020	28/F	9.5	NR	NR	NR	Yes (NAC + RT + surgery)	No	No	NAC (API/AI)	NED/5 mo	(8)
Bode-Lesniewska B, 2019	42/M	NR	NGS	Diaphyseal cortex	MET	Curettage, resection 1 year later; amputation 7.5 years post-op due to surgical complications	No	No	No	NED/102 mo	(16)
Yoshida K, 2020	78/F	NR	NR	NR	NR	NR	NR	NR	NR	NR/NR	(4)
Tsuda Y, 2020	78/M	NR	NR	Diaphyseal medulla	NR	NR	NR	NR	NR	NR/NR	(17)
Present study	38 ^a /M	6.6	RT-PCR, direct sequencing	Metaphyseal cortex	EAD	Wide resection	No	NR	VDC/VAC Eribulin Trabectedin Pazopanib	AWD/56 mo	-

^aAge at initial diagnosis. AI, adriamycin and ifosfamide; API, adriamycin, cisplatin, and ifosfamide; AWD, alive with disease; EAD, Ewing-like adamantinoma; ES, Ewing sarcoma; F, female; IE, ifosfamide and etoposide; M, male; MET, myoepithelial tumor; mo, month(s); NAC, neoadjuvant chemotherapy; NED, no evidence of disease; NGS, next generation sequencing; NR, not reported; RT, radiation therapy; RT-PCR, reverse transcription-polymerase chain reaction; VAC, vincristine, actinomycin D, and cyclophosphamide; VDC, vincristine, doxorubicin, and cyclophosphamide.